Evaluations of metabolic and innate immunity profiles in subjects with familial hypercholesterolemia with or without subclinical atherosclerosis

Abstract

Aim: Familial hypercholesterolemia (FH) is a genetic condition characterized by high low-density lipoprotein cholesterol (LDL-C). The presence of risk modifiers could promote the atherosclerotic injury beyond LDLC. Our aim was to evaluate metabolic and innate immunity profiles in FH subjects with or without subclinical atherosclerosis.
Methods: In this cross-sectional observational study, we evaluated 211 genetically confirmed FH subjects on LDLC target and without cardiovascular diseases. Biochemical analyses, LDL-C burden (LCB) calculation and vascular profile evaluation were obtained from all subjects. Study population was divided into two groups according to subclinical atherosclerosis: the subclinical atherosclerosis (SA) group and non-subclinical atherosclerosis (NSA) group.
Results: SA group had higher LDL-C at diagnosis (288.35±24.52 vs 267.92±23.86, p<0.05) and LCB (13,465.84±3617.46 vs 10,872.63±3594.7, p<0.001) than NSA group. SA group had higher white blood cell count (WBCC, 6.9±1.66 vs 6.1±1.16), neutrophil count (NC, 4.2±1.3 vs 3.6±1.11), monocyte count (MC, 0.8±0.2 vs 0.4±0.1), triglyceride to high-density lipoprotein ratio (TG/HDL, 1.73±0.72 vs 1.45±0.69), triglyceride-glucose index (TyG, 8.29±0.35 vs 8.01±0.33) than NSA group (p value for all <0.01). Multivariate logistic regression analysis showed that LCB (p<0.01), WBCC (p<0.01), NC (p<0.05), MC (p<0.05) were associated with subclinical atherosclerosis. Simple linear regression analyses showed that LCB was associated with WBCC, NC, MC (p value for all <0.01).
Conclusion: An increased LCB and an impaired innate immunity profile were found in FH subjects with subclinical atherosclerosis and they were independently associated with atherosclerotic injury. LCB could modulate the innate immunity profile.